 Home > Encyclopedia > Capreomycin

Capreomycin

Capreomycin structure

CAS No:
11003-38-6
Chemical Name:
Capreomycin
Synonyms:
Capreomycin;Capromycin;Capastat;Capostatin;Capreomicin;37307-68-9
Categories:
Active Pharmaceutical Ingredients > Antibiotics

Description

Capreomycin is a kind of antibiotics for the treatment of tuberculosis. It should be noted that it is for second line treatment, being used for targeting active drug resistant tuberculosis. It is mainly used for the treatment of mycobacterium tuberculosis. It is a cyclic peptide antibiotic similar to viomycin, being produced by Streptomyces capreolus. It belongs to the aminoglycoside family of antibiotics. The exact mechanism of action of capreomycin is largely unknown. It is indicated that it

Capreomycin Basic Attributes

Molecular Weight：

1321.41

Exact Mass：

766.314026

Characteristics

PSA：

480.83000

Boiling Point：

1376.7ºC at 760 mmHg

Flash Point：

786.4ºC

Capreomycin Use and Manufacturing

Methods of Manufacturing

The product producing bacteria is Streptomyces curlyi. The fermentation broth is used to obtain fermentation broth, which is purified and concentrated by weak acid acrylic cation exchange resin, and then desalted by strong acid styrene cation exchange resin, decolorized by weak acid acrylic cation exchange resin, and film. concentrate. The concentrated solution is decolorized, heat-removed, sterile filtered, and spray dried to obtain the finished product.

Uses

Capreomycin is a complex of cyclic pentopeptides isolated from Streptomyces capreolus, first reported in 1962. The complex has two major components, IA and IB, with an exocyclic lysine residue and two minor delysinyl components, IIA and IIB. Capreomycin is a potent antibiotic with activity against mycobateria, Gram positive and Gram negative organisms. Capreomycin acts by binding to the 23S ribosomal subunit, disrupting protein synthesis.

Drug Function and Efficacy

This product is a polypeptide complex that has an inhibitory effect on Mycobacterium tuberculosis. The mechanism is not clear yet, but it may be related to the inhibition of bacterial protein synthesis. Bacteria are prone to develop drug resistance when used alone. This product has incomplete cross-resistance with kanamycin and puromycin.

This ingredient has been used in drugs with the following functions (note: it does not mean that the ingredient itself has the following health functions)

Related Drugs

Capreomycin Sulfate for Injection
Ingredients	This product only contains capreomycin
Indication	1. When used in combination with aminoglycosides, it may increase the possibility of ototoxicity, nephrotoxicity and neuromuscular blockade. Hearing loss may occur, which may be temporary and may continue to progress to deafness after drug withdrawal, often permanently. Neuromuscular blockade can lead to skeletal muscle weakness and respiratory depression or respiratory muscle paralysis, which can be helped by anticholinesterase drugs or calcium salts. 2. When used simultaneously or successively with amphotericin B, vancomycin, bacitracin, paromomycin, cyclosporine, carmustine, cisplatin, bumetanide, ethacrynic acid and furosemide, it may increase the possibility of ototoxicity and nephrotoxicity. Hearing and renal function tests should be performed regularly when used together. 3. Antihistamines, buclizine, cyclisone, meclizine, phenothiazines, thioxanthenes and trimethoprim-butyl amine may mask ototoxic symptoms such as tinnitus, dizziness or vertigo when used in combination with this product. 4 When used in combination with anti-neuromuscular blocking drugs, it can antagonize the latter's effects on skeletal muscles. Therefore, the dose of anti-myasthenic drugs needs to be adjusted at the time of or after combined use. 5 When methoxyflurane or polymyxin injections are used simultaneously or successively with this product, renal toxicity or neuromuscular blocking effects may increase, so combined use should be avoided; neuromuscular blocking effects can cause skeletal muscle weakness and respiratory depression or respiratory muscle paralysis; during or after surgery, this product should also be used with caution when used in combination with the two, and anticholinesterase drugs or calcium salts can help blockade recovery. 6 When this product is used in combination with opioid analgesics, the central respiratory depressant effects of the two may be additive, resulting in aggravated respiratory depression or prolonged depression or respiratory paralysis, and close observation and follow-up are required.
Specifications	0.5g
Manufacturer	Henan Taifeng Biotechnology Co., Ltd.

Capreomycin Sulfate for Injection
Ingredients	This product only contains capreomycin
Indication	1. When used in combination with aminoglycosides, it may increase the possibility of ototoxicity, nephrotoxicity and neuromuscular blockade. Hearing loss may occur, which may be temporary and may continue to progress to deafness after drug withdrawal, often permanently. Neuromuscular blockade can lead to skeletal muscle weakness and respiratory depression or respiratory muscle paralysis, which can be helped by anticholinesterase drugs or calcium salts. 2. When used simultaneously or successively with amphotericin B, vancomycin, bacitracin, paromomycin, cyclosporine, carmustine, cisplatin, bumetanide, ethacrynic acid and furosemide, it may increase the possibility of ototoxicity and nephrotoxicity. Hearing and renal function tests should be performed regularly when used together. 3. Antihistamines, buclizine, cyclisone, meclizine, phenothiazines, thioxanthenes and trimethoprim-butyl amine may mask ototoxic symptoms such as tinnitus, dizziness or vertigo when used in combination with this product. 4 When used in combination with anti-neuromuscular blocking drugs, it can antagonize the latter's effects on skeletal muscles. Therefore, the dose of anti-myasthenic drugs needs to be adjusted at the time of or after combined use. 5 When methoxyflurane or polymyxin injections are used simultaneously or successively with this product, renal toxicity or neuromuscular blocking effects may increase, so combined use should be avoided; neuromuscular blocking effects can cause skeletal muscle weakness and respiratory depression or respiratory muscle paralysis; during or after surgery, this product should also be used with caution when used in combination with the two, and anticholinesterase drugs or calcium salts can help blockade recovery. 6 When this product is used in combination with opioid analgesics, the central respiratory depressant effects of the two may be additive, resulting in aggravated respiratory depression or prolonged depression or respiratory paralysis, and close observation and follow-up are required.
Specifications	0.5g (500,000 units)
Manufacturer	Zhejiang Hisun Pharmaceutical Co., Ltd.

Capreomycin Sulfate for Injection
Ingredients	This product only contains capreomycin
Indication	1. When used in combination with aminoglycosides, it may increase the possibility of ototoxicity, nephrotoxicity and neuromuscular blockade. Hearing loss may occur, which may be temporary and may continue to progress to deafness after drug withdrawal, often permanently. Neuromuscular blockade can lead to skeletal muscle weakness and respiratory depression or respiratory muscle paralysis, which can be helped by anticholinesterase drugs or calcium salts. 2. When used simultaneously or successively with amphotericin B, vancomycin, bacitracin, paromomycin, cyclosporine, carmustine, cisplatin, bumetanide, ethacrynic acid and furosemide, it may increase the possibility of ototoxicity and nephrotoxicity. Hearing and renal function tests should be performed regularly when used together. 3. Antihistamines, buclizine, cyclisone, meclizine, phenothiazines, thioxanthenes and trimethoprim-butyl amine may mask ototoxic symptoms such as tinnitus, dizziness or vertigo when used in combination with this product. 4 When used in combination with anti-neuromuscular blocking drugs, it can antagonize the latter's effects on skeletal muscles. Therefore, the dose of anti-myasthenic drugs needs to be adjusted at the time of or after combined use. 5 When methoxyflurane or polymyxin injections are used simultaneously or successively with this product, renal toxicity or neuromuscular blocking effects may increase, so combined use should be avoided; neuromuscular blocking effects can cause skeletal muscle weakness and respiratory depression or respiratory muscle paralysis; during or after surgery, this product should also be used with caution when used in combination with the two, and anticholinesterase drugs or calcium salts can help blockade recovery. 6 When this product is used in combination with opioid analgesics, the central respiratory depressant effects of the two may be additive, resulting in aggravated respiratory depression or prolonged depression or respiratory paralysis, and close observation and follow-up are required.
Specifications	1.0g (1 million units)

See More Related Drugs